TY - JOUR
T1 - Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer
T2 - Focus on TLR9 agonists, IMiDs and NGR-TNF
AU - Corti, Angelo
AU - Giovannini, Monica
AU - Belli, Carmen
AU - Villa, Eugenio
PY - 2010
Y1 - 2010
N2 - Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory results to be widely applied in the clinical practice. However, the recent development of new immunomodulatory agents may open promising therapeutic options. This paper focuses on PF3512676, lenalidomide, and NGR-TNF, that is, drugs belonging to three different classes of immunomodulatory agents, that are also capable to affect tumor blood vessels with different mechanisms, and discusses the potential role of such agents in NSCLC treatment strategy.
AB - Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory results to be widely applied in the clinical practice. However, the recent development of new immunomodulatory agents may open promising therapeutic options. This paper focuses on PF3512676, lenalidomide, and NGR-TNF, that is, drugs belonging to three different classes of immunomodulatory agents, that are also capable to affect tumor blood vessels with different mechanisms, and discusses the potential role of such agents in NSCLC treatment strategy.
UR - http://www.scopus.com/inward/record.url?scp=77954649329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954649329&partnerID=8YFLogxK
U2 - 10.1155/2010/732680
DO - 10.1155/2010/732680
M3 - Article
C2 - 20613952
AN - SCOPUS:77954649329
JO - Journal of Oncology
JF - Journal of Oncology
SN - 1687-8450
M1 - 732680
ER -